Published Paper Details:

The emergence of 3D printing (additive manufacturing) has transformed many sectors transparently, including pharmaceuticals where it can provide a precise method for producing complex and patient-specific dosage forms. This has great promise in personalized medicine, drug delivery tailoring, and improving patient adherence. Of all 3D printing technology, for example FDM, SLA and SLS etc., each of which has its own strengths and limitations, they have gained popularity in pharmaceutical research due to their utilization benefits. FDM is particularly accessible and affordable, while SLA if known for its.and SLS are capable of complex geometries with no additional supporting structures. Materials science has developed rapidly and is still developing, particularly in terms of biocompatible polymers, nanocomposite materials, as well as biodegradable materials, thus broadening the application field of 3D printing to drug formulation and implant design [1]. However, there are processes of optimization to be followed, ways to adhere in the regulations and materials and methods routines. Both academia and regulatory agencies need to work together to create a set of safety guidelines and guidelines capable of effectively integrate this new technology in the conventional production of pharmaceuticals. Overall, 3D printing holds significant promise to transform patient-centred treatment, promote customized therapies, and advance the future of pharmaceutical innovation.